Skip to content

Microbiom-gut-brain interaction in Anorexia nervosa

Microbiom-gut-brain interaction in Anorexia nervosa - MiGBAN

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00017726
Enrollment
90
Registered
2019-08-30
Start date
2019-11-08
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F50.0

Interventions

Group 1: Anorexia nervosa patients receive a daily dose (1 sacket that is 3000mg) of a freely available multi-strain probioticum (Lactobacilli and Bifidobacteria) for 6 months. Group 2: Anorexia nervo

Sponsors

Medical University of Vienna, Department of Child and Adolescent Psychiatry, Eating Disorder Unit
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 19 Years

Inclusion criteria

Inclusion criteria: 1. Female and male patients >=13 and <20 2. Written Informed consent. 3. Patient with typical and atypical anorexia nervosa according to DSM-5 4. Healthy control subjects without current psychiatric disorder according to ICD-10 and without eating disorders in the past.

Exclusion criteria

Exclusion criteria: 1. Organic brain disease 2. psychotic disorder 3. bipolar disorder 4. substance use disorder 5. insufficient knowledge of German language 6. Organic disorder with influence on gastrointestinal tract for example diabetes or inflammtory bowel diseases 7. antibiotic use during the previous 6 weeks. 8. pregnancy

Design outcomes

Primary

MeasureTime frame
Approximation of microbiome (MI) composition after probiotica administration to that of heathly normal-weight age-matched controls which in consequence leads an increase in body weight as measured in body mass index. Measurement times are 6 and 12 months after inclusion in the study. Assessments include psychological tests, pathopsychological questionnaires, blood-samples, stool-samples and functional MRI at each measurement time.

Secondary

MeasureTime frame
Secondarily, an improvement in gastrointestinal discomfort, a reduction in depressive symptoms and a reduction in inflammatory processes and intestinal permeability may be associated with these MI changes. Measurement times are 6 and 12 months after inclusion in the study. Assessments include psychological tests, pathopsychological questionnaires, blood-samples, stool-samples and functional MRI at each measurement time.

Countries

Austria

Contacts

Public ContactAndreas Karwautz

Medical University of Vienna, Department of Child and Adolescent Psychiatry, Eating Disorder Unit

andreas.karwautz@meduniwien.ac.at+43-1-40400-30120

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026